The estimated Net Worth of Bros. Capital (Gp), Llcbake... is at least $45.3 Million dollars as of 7 June 2011. Bros Llcbake owns over 119 units of Seagen Inc stock worth over $44,493,817 and over the last 21 years Bros sold SGEN stock worth over $821,118.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Bros Llcbake SGEN stock SEC Form 4 insiders trading
Bros has made over 16 trades of the Seagen Inc stock since 2003, according to the Form 4 filled with the SEC. Most recently Bros bought 119 units of SGEN stock worth $3,117 on 7 June 2011.
The largest trade Bros's ever made was buying 107,650 units of Seagen Inc stock on 19 September 2003 worth over $542,556. On average, Bros trades about 4,410 units every 59 days since 2003. As of 7 June 2011 Bros still owns at least 194,415 units of Seagen Inc stock.
You can see the complete history of Bros Llcbake stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Insiders trading at Seagen Inc
Over the last 22 years, insiders at Seagen Inc have traded over $729,924,224 worth of Seagen Inc stock and bought 35,347,908 units worth $1,433,871,526 . The most active insiders traders include Bros. Advisors Lp667, L.P.B..., Felixbaker Julian Baker Bro..., and Brothers Life Sciences Capi.... On average, Seagen Inc executives and independent directors trade stock every 8 days with the average trade being worth of $18,157,295. The most recent stock trade was executed by David R Epstein on 10 November 2023, trading 10,620 units of SGEN stock currently worth $2,262,166.
What does Seagen Inc do?
seattle genetics, co-founded by clay siegall, is a biotechnology company leading the field of antibody-drug conjugates (adcs) for the treatment of cancer. our technology is designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. our lead program, adcetris® (brentuximab vedotin), is the first in a new class of adcs and, in collaboration with takeda pharmaceutical company limited, is approved in more than 55 countries. to expand on the adcetris opportunity, we are conducting a broad clinical development program to evaluate its therapeutic potential in a range of other lymphoma and non-lymphoma settings. seattle genetics is also advancing a robust pipeline of clinical-stage programs, including sgn-cd19a, sgn-cd33a, sgn-liv1a, sgn-cd70a, asg-22me, asg-15me and sea-cd40. seattle genetics has collaborations for its adc technology with a number of leading biotechnology and pharmaceutical companies, including abbvie, agensys
What does Seagen Inc's logo look like?
Complete history of Bros Llcbake stock trades at Biocryst Pharmaceuticals, Incyte, and Seagen Inc
Seagen Inc executives and stock owners
Seagen Inc executives and other stock owners filed with the SEC include:
-
Clay Siegall,
Chairman of the Board, President, Chief Executive Officer -
Roger Dansey,
Chief Medical Officer -
Todd Simpson,
Chief Financial Officer -
Jean Liu,
Executive Vice President - Legal Affairs, General Counsel, Corporate Secretary -
Vaughn Himes,
Chief Technical Officer -
Dr. Clay B. Siegall,
Co-Founder, Chairman, Pres & CEO -
Dr. Roger D. Dansey M.D.,
Chief Medical Officer & Interim CEO -
Jean I. Liu,
Gen. Counsel, Exec. VP of Legal Affairs & Corp. Sec. -
Jean I. Liu J.D., M.S.,
Chief Legal Officer -
Charles R. Romp,
Exec. VP of Commercial U.S. -
Todd E. Simpson,
Chief Financial Officer -
Felix Baker,
Lead Independent Director -
David Gryska,
Independent Director -
John Orwin,
Independent Director -
Nancy Simonian,
Independent Director -
Alpna Seth,
Independent Director -
Daniel Welch,
Independent Director -
Marc Lippman,
Independent Director -
Ted Love,
Director -
David Caouette,
VP of Corp. Communications -
Dr. Vaughn B. Himes,
Chief Technical Officer -
Christopher P. Pawlowicz,
Exec. VP of HR -
Matt Skelton,
VP of Marketing -
Natasha A. Hernday,
Exec. VP of Corp. Devel. & Alliance Management -
Nancy Whiting B.Sc., Pharm.D.,
Exec. VP of Corp. Strategy, Alliances & Communications -
Peggy Pinkston,
VP of Investor Relations -
Bros. Advisors Lp Baker Bro...,
-
Bros. Advisors Lp Baker Bro...,
-
Felixbaker Julian Baker Bro...,
-
Srinivas Akkaraju,
Director -
Eric Dobmeier,
Vice President, -
Bros. Advisors Lp667, L.P.B...,
-
Sandra M Swain,
-
Morgan Partners Bhca Lpjpmp...,
-
/ Tisch Capital (Gp), Llcba...,
-
Biotech Capital (Gp), Llcba...,
-
Robin G Taylor,
Chief Commercial Officer -
Felix667, L.P.Baker Julian ...,
-
John Peter Mclaughlin,
Director -
Felix Baker,
Director -
Morris Rosenberg,
SVP, Development -
Bruce J. Seeley,
EVP, Commerical -
Felix667, L.P.Baker Brother...,
-
Thomas C Reynolds,
Chief Medical Officer -
Christopher S. Boerner,
SVP, Commercial -
Brothers Life Sciences Capi...,
-
Capital (Gp), Llcbaker Juli...,
-
Holdings, Inc.H&Q Employee ...,
-
Bros. Capital (Gp), Llcbake...,
-
Bros. Advisors Lp667, L.P.B...,
-
Darren S Cline,
SVP, Commercial -
Morgan Partners Bhca Lpjpmp...,
-
Felixbaker Julian Baker Bro...,
-
Franklin M Berger,
Director -
Morgan Partners Bhca Lp Jp,
10% owner -
Daniel Floyd Jr Hoth,
Director -
Morgan Partners Bhca Lpjpmp...,
-
Morgan Partners Bhca Lpjpmp...,
-
Jonathan Gallen,
10% owner -
Management Partners Vi Llcd...,
-
Pamela A Trail Smith,
Chief Scientific Officer -
Brothers Life Sciences Capi...,
-
Biotech Capital Ii Gp Llcba...,
-
Morgan Partners Bhca Lpjpmp...,
-
Morgan Partners Bhca Lpjpmp...,
-
Biotech Capital Ii (Z) (Gp)...,
-
Amy Sing,
Sr. Director Medical Affairs -
Michael Powell,
Director -
Biotech Capital Iii (Z) (Gp...,
-
Tim Carroll,
CFO -
Investment Llc Cascade,
-
Douglas Southern,
Director -
Karl Erik Hellstrom,
Director -
Michael Mcdonald,
Chief Medical Officer -
Morgan Partners Bhca Lpjpmp...,
-
Peter Senter,
Vice President, Chemistry -
H Perry Fell,
Chairman -
Bros. Advisors Lp Baker Bro...,
-
Bros. Advisors Lp667, L.P.B...,
-
David R Epstein,
CEO -
Charles R Romp,
EVP, Commercial U.S.